What's Happening?
Mission Bio has unveiled data demonstrating the capabilities of its Tapestri Platform in analyzing CRISPR-engineered T cells. The platform's Targeted Single-Cell DNA+RNA Assay can resolve CRISPR edit co-occurrence, allelic zygosity, and gene expression
changes in individual cells. This advancement addresses the limitations of legacy bulk assays, which average signals across millions of cells, masking critical heterogeneity and off-target events. The findings will be presented at the American Society of Gene & Cell Therapy Annual Meeting, highlighting the platform's ability to provide detailed safety evidence required by regulators.
Why It's Important?
Mission Bio's single-cell analysis technology represents a significant advancement in the field of gene editing and cell therapy. By providing detailed insights into CRISPR edits at the single-cell level, the Tapestri Platform enhances the safety and efficacy of engineered T cell therapies. This capability is crucial for meeting regulatory requirements and advancing personalized medicine. The technology's ability to identify rare cell populations and therapeutic resistance mechanisms could lead to more effective treatments for complex diseases, benefiting patients and the healthcare industry.
